Posterior Reversible Encephalopathy Syndrome Induced by Anti-VEGF Agents

Overview

Journal Target Oncol

Specialty Oncology

Date 2011 Nov 18

PMID 22090260

Citations 43

Authors

Camille Tlemsani

Olivier Mir

Pascaline Boudou-Rouquette

Olivier Huillard

Karin Maley

Stanislas Ropert

Romain Coriat

Francois Goldwasser

Affiliations

Soon will be listed here.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents.

Citing Articles

Posterior reversible encephalopathy syndrome associated with antibiotic therapy: a case report and systematic review.

Barba L, Carrubba C, Spindler K, Weise C, Sachs T, Foschi M Neurol Sci. 2024; 45(9):4151-4159.

PMID: 38679625 PMC: 11306538. DOI: 10.1007/s10072-024-07545-1.

Tacrolimus-associated neurotoxicity isolated to the brainstem: two illustrative cases and a systematic review of the literature.

Rossi S, Rinaldi R, Asioli G, Barone V, Pianta P, Cescon M Neurol Sci. 2024; 45(7):3107-3115.

PMID: 38460049 DOI: 10.1007/s10072-024-07433-8.

Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice.

Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G Cancers (Basel). 2024; 16(2).

PMID: 38254839 PMC: 10813960. DOI: 10.3390/cancers16020350.

Posterior reversible encephalopathy syndrome associated with use of anlotinib to treat squamous cell carcinoma of the cervix: case report and literature review.

Lin J, Chen W, Zhong S, Qian K, Chen H, Lin L Front Pharmacol. 2024; 14:1255785.

PMID: 38169843 PMC: 10758437. DOI: 10.3389/fphar.2023.1255785.

Supratentorial hemangioblastoma: correlation between phenotype, gender and vascular territory affected.

Laviv Y, Saraf D, Oxman L, Ben Zvi I Neurosurg Rev. 2023; 46(1):281.

PMID: 37875641 DOI: 10.1007/s10143-023-02194-y.

References

Kapiteijn E, Brand A, Kroep J, Gelderblom H . Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007; 18(10):1745-7. DOI: 10.1093/annonc/mdm454. View

Feldman D, Baum M, Ginsberg M, Hassoun H, Flombaum C, Velasco S . Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(9):1432-9. PMC: 3655420. DOI: 10.1200/JCO.2008.19.0108. View

Lou E, Turner S, Sumrall A, Reardon D, Desjardins A, Peters K . Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011; 29(28):e739-42. DOI: 10.1200/JCO.2011.36.1865. View

Izzedine H, Ederhy S, Goldwasser F, Soria J, Milano G, Cohen A . Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009; 20(5):807-15. DOI: 10.1093/annonc/mdn713. View

Seet R, Rabinstein A . Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM. 2011; 105(1):69-75. DOI: 10.1093/qjmed/hcr139. View

El Maalouf G, Mitry E, Lacout A, Lievre A, Rougier P . Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. J Neurol. 2008; 255(2):295-6. DOI: 10.1007/s00415-008-0692-2. View

Tsatsaris V, Goffin F, Munaut C, Brichant J, Pignon M, Noel A . Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003; 88(11):5555-63. DOI: 10.1210/jc.2003-030528. View

Lau P, Paunipagar B . Posterior reversible encephalopathy syndrome with bevacizumab. Hong Kong Med J. 2011; 17(1):80-1. View

Govindarajan R, Adusumilli J, Baxter D, El-Khoueiry A, Harik S . Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006; 24(28):e48. DOI: 10.1200/JCO.2006.08.4608. View

10.

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A . A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996; 334(8):494-500. DOI: 10.1056/NEJM199602223340803. View

11.

Cumurciuc R, Martinez-Almoyna L, Henry C, Husson H, De Broucker T . Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris). 2008; 164(6-7):605-7. DOI: 10.1016/j.neurol.2008.03.007. View

12.

van der Veldt A, van den Eertwegh A, Hoekman K, Barkhof F, Boven E . Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol. 2007; 18(10):1747-50. DOI: 10.1093/annonc/mdm455. View

13.

Burki F, Badie K, Bartoli P, Bernard P, Montastruc J, Bagheri H . Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. Br J Clin Pharmacol. 2008; 65(5):793-4. PMC: 2432493. DOI: 10.1111/j.1365-2125.2008.03119.x. View

14.

Hinchey J . Reversible posterior leukoencephalopathy syndrome: what have we learned in the last 10 years?. Arch Neurol. 2008; 65(2):175-6. DOI: 10.1001/archneurol.2007.62. View

15.

Koopman M, Muller E, Punt C . Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case. Dis Colon Rectum. 2008; 51(9):1425-6. DOI: 10.1007/s10350-008-9282-8. View

16.

Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H . Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. J Ocul Pharmacol Ther. 2010; 26(3):301-3. DOI: 10.1089/jop.2009.0148. View

17.

Feske S . Posterior reversible encephalopathy syndrome: a review. Semin Neurol. 2011; 31(2):202-15. DOI: 10.1055/s-0031-1277990. View

18.

Mir O, Ropert S, Alexandre J, Goldwasser F . Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol. 2009; 20(5):967-70. DOI: 10.1093/annonc/mdp206. View

19.

Dogan E, Aksoy S, Arslan C, Dede D, Altundag K . Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2009; 27(4):1436-7. DOI: 10.1007/s12032-009-9378-6. View

20.

Wagner S, Acquah L, Lindell E, Craici I, Wingo M, Rose C . Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control. Mayo Clin Proc. 2011; 86(9):851-6. PMC: 3258001. DOI: 10.4065/mcp.2011.0090. View